DelveInsight’s Systemic Lupus Erythematosus Market Insights report includes a comprehensive understanding of current treatment practices, emerging systemic lupus erythematosus drugs, market share of ...

A new study found statin use is associated with reduced disease activity and inflammation in people with systemic lupus ...

Systemic lupus erythematosus (SLE) is the most common type of lupus, a chronic autoimmune disease. Symptoms include fatigue, joint pain, and rashes across your nose and cheeks. While there’s no cure, ...

SIGLEC‑1 expression correlates with disease activity in patients with lupus erythematosus during type I interferon blockade ...

Patients with systemic lupus erythematosus who receive belimumab monotherapy show comparable remission rates and disease control to those who receive combination therapy with immunosuppressants.

Systemic lupus erythematosus (SLE) is a complex and potentially life-threatening autoimmune disease. Part of the complexity stems from how it can differ from person to person—giving rise to marked ...

Blood dendritic cell antigen 2 (BDCA2) is a receptor that is exclusively expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of lupus erythematosus. Whether treatment ...

This page lists all known medications that could potentially lead to 'Drug-induced lupus erythematosus' as a side effect. It's important to note that mild side effects are quite common with ...

This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major ...